{"id":243037,"date":"2012-06-19T06:14:51","date_gmt":"2012-06-19T06:14:51","guid":{"rendered":"http:\/\/www.eugenesis.com\/bruker-and-the-cdc-special-bacteriology-reference-laboratory-announce-a-collaboration-for-mass-spectrometry-based\/"},"modified":"2012-06-19T06:14:51","modified_gmt":"2012-06-19T06:14:51","slug":"bruker-and-the-cdc-special-bacteriology-reference-laboratory-announce-a-collaboration-for-mass-spectrometry-based","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/microbiology\/bruker-and-the-cdc-special-bacteriology-reference-laboratory-announce-a-collaboration-for-mass-spectrometry-based.php","title":{"rendered":"Bruker and the CDC Special Bacteriology Reference Laboratory Announce a Collaboration for Mass Spectrometry-based &#8230;"},"content":{"rendered":"<p><p>    SAN FRANCISCO--(BUSINESS WIRE)--  <\/p>\n<p>    At the 112th General Meeting of the American Society of    Microbiology (ASM) in San Francisco, Bruker announces a new    collaboration with the Special Bacteriology Reference    Laboratory (SBRL) of the U.S. Centers for Disease Control and    Prevention (CDC).  <\/p>\n<p>    The SBRL receives approximately 800 isolates of rare and    unusual bacteria from U.S. public health laboratories (PHLs)    each year for identification. SBRL maintains a culture    collection of over 90,000 isolates that have been received over    the past 60 years. Currently, SBRL uses a polyphasic approach    to identify unusual bacteria, including both traditional    microbiological and molecular testing. Traditional biochemical    tests may take weeks to complete. Molecular methods, i.e. 16S    rRNA gene sequencing, are more rapid, but the public sequence    databases may be incomplete and contain erroneous sequences.  <\/p>\n<p>    MALDI-TOF testing can be completed in hours and therefore has    the potential to produce more rapid results than traditional    microbiological testing methods. The goals of this announced    collaboration include: validation and expansion of the Bruker    MALDI Biotyper database of protein fingerprint    profiles for identification of unusual bacterial pathogens;    evaluation of the use of the Bruker MALDI    Biotyper as a replacement for or in conjunction with    traditional biochemical testing in order to decrease the time    needed for accurate identification of bacteria.  <\/p>\n<p>    During the collaboration period of one year, each bacterial    isolate received by SBRL will be tested using the MALDI    Biotyper, traditional phenotypic and 16S ribosomal RNA    gene sequencing to validate the results. In addition, type    strains of known bacteria will be tested by the three methods.    MALDI-TOF will be evaluated for accuracy, reproducibility, and    ease of use. Data will be analyzed to determine the value of    adding MALDI-TOF to the SBRL testing algorithm.  <\/p>\n<p>    This research collaboration will enhance the MALDI    Biotyper database as well as determine if the MALDI-TOF    platform can complement the other testing methods currently    used by SBRL and the US PHLs for bacterial identification.  <\/p>\n<p>    Dr. Gongyi Shi, Director of Scientific Affairs in the    Microbiology business of Bruker Daltonics, commented: We are    very excited to establish this collaboration with CDCs Special    Bacteriology Reference Laboratory. The MALDI    Biotyper has been demonstrated to have superior    performance, compared to classical identification methods, for    common bacteria representing roughly 95% of the isolates in    most clinical microbiology laboratories. With SBRLs worldwide    acknowledged expertise in the field and large collection of    bacteria, especially those rare and unusual bacteria, we will    further improve the coverage of the MALDI    Biotyper reference library. Over time, this will allow    us to provide an even better solution to our customers.  <\/p>\n<p>    About the Bruker MALDI Biotyper  <\/p>\n<p>    Bruker's dedicated MALDI Biotyper solution    enables molecular identification, taxonomical classification or    dereplication of microorganisms like bacteria, yeasts and    fungi. Classification and identification of microorganisms is    achieved reliably and fast using proteomic fingerprinting with    high-throughput MALDI-TOF mass spectrometry. Applications    include clinical routine microbial identification,    environmental and pharmaceutical analysis, taxonomical    research, food and consumer product processing and quality    control, as well as in marine microbiology. Bruker's robust    MALDI Biotyper method requires minimal sample    preparation efforts and offers low cost per sample. The    MALDI Biotyper is available in a    research-use-only version, as well as in an IVD version    according to the EU directive EC\/98\/79 in various EU countries.    For more information, please visit     <a href=\"http:\/\/www.bruker.com\/MALDIBiotyper\" rel=\"nofollow\">http:\/\/www.bruker.com\/MALDIBiotyper<\/a>  <\/p>\n<p>    About Bruker Corporation  <\/p>\n<\/p>\n<p>See the rest here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/bruker-cdc-special-bacteriology-reference-130000958.html;_ylt=A2KJNTvSGOBPkAgA3sn_wgt.\" title=\"Bruker and the CDC Special Bacteriology Reference Laboratory Announce a Collaboration for Mass Spectrometry-based ...\">Bruker and the CDC Special Bacteriology Reference Laboratory Announce a Collaboration for Mass Spectrometry-based ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SAN FRANCISCO--(BUSINESS WIRE)-- At the 112th General Meeting of the American Society of Microbiology (ASM) in San Francisco, Bruker announces a new collaboration with the Special Bacteriology Reference Laboratory (SBRL) of the U.S.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/microbiology\/bruker-and-the-cdc-special-bacteriology-reference-laboratory-announce-a-collaboration-for-mass-spectrometry-based.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577473],"tags":[],"class_list":["post-243037","post","type-post","status-publish","format-standard","hentry","category-microbiology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/243037"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=243037"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/243037\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=243037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=243037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=243037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}